The Nicholas Piramal Group is ramping up its production figures by shifting Haemaccel manufacturing facility from Mumbai to Baddi in Himachal Pradesh shortly.
Ajay Piramal and Swati Piramal, chairman and director, strategic alliances said on Sunday that Haemaccel is a life saving product generally used as volume replacement in severe blood loss. This facility shall be built up with the estimated investment of 30 crore. This new facility is expected to start the commercial production by end of 2008.
Nicholas Piramal is one of leading pharmaceutical companies in India with turnover close to Rs 3,000 crore. The Piramal Group also deals in glass, diagnostic centres, pharma research and development with total turnover of around Rs 5000 crore.
The group is adopting a new identity and the pharma business will be reschristened as Piramal Healthcare Ltd soon.
Nicholas Piramal in 2006 had made Rs 170 crore investment in Baddi by setting up new facility. This is the highest investment by any pharma plant in this place. The plant with the area covering 36,000 sq metre was setup within a record period of 12 months.